Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 8/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.52 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 5/20 | 0.39 |
| ▸ | PPARA | Q07869 | 5/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005251 | 0.84 | PTGDR (0.55) | PTGDRPTGDR2PPARGKDM4EMEN1 | |
| SCHEMBL2004566 | 0.79 | CYP3A4 (0.39) | PTGDRPTGDR2PPARGKDM4EMEN1 | |
| SCHEMBL2000430 | 0.77 | PTGDR2 (0.42) | PTGDRPTGDR2PPARGKDM4EMEN1 | |
| SCHEMBL2002108 | 0.76 | PTGDR (0.87) | PTGDRPTGDR2CYP3A4 | |
| SCHEMBL2004735 | 0.75 | CYP3A4 (0.56) | PTGDRPTGDR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL2010966 | 0.74 | CYP3A4 (0.45) | PTGDRPTGDR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL12570787 | 0.72 | PTGDR2 (0.46) | PTGDRPTGDR2PPARGKDM4EMEN1 | |
| SCHEMBL14819909 | 0.71 | PPARD (0.40) | PTGDRPTGDR2PPARGMAPTPPARD | |
| SCHEMBL12570790 | 0.71 | PTGDR (0.59) | PTGDRPTGDR2KDM4EMEN1ALDH1A1 | |
| SCHEMBL2003571 | 0.71 | PPARD (0.40) | PTGDRPTGDR2PPARGKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164828-B1 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2164828-B1 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2164828-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | Amgen Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008137027-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137027-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | CCL11, LTC4S, TSLP | PTGDR 296/4885PTGDR2 253/4885PPARG 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.